User talk:Antiqueight and Jerini: Difference between pages

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia
(Difference between pages)
Content deleted Content added
VisualWikitext
Giving DYK credit for Janet McNeill on behalf of Amberrock
 
 
Line 1: Line 1:
== Jerini AG ==
{{User:Antiqueight/HalloweenNavbar}}
[[image:jerini_285_93.jpg|left]] Jerini is a pharmaceutical company based in Berlin, Germany, focusing on the
{{YesAutosign}}
discovery and development of novel peptide-based drugs. Using its proprietary
technology platform, Peptides-to-Drugs (P2D), Jerini pursues disease indications
for which limited, inadequate, or no treatment options exist. As a result, Jerini
has established a drug pipeline composed of its own programs as well as others
in collaboration with partners. Jerini's commercialization strategy is to market
new drugs in niche indications independently and in larger indications with
partners.


{| class="wikitable"|border: none
|+ '''<u>Welcome</u>'''
|-
| style="padding-left: 8em;"| I am still learning my way around the place. I will make mistakes. Contact me if I do and we can talk.
|-
| style="padding-left: 8em;"| <span class="plainlinks">[http://en.wikipedia.org/w/index.php?title=User_talk:Antiqueight&action=edit&section=new '''Click here''']</span> to leave me a message. Please don't forget to sign.
|-
|style="padding-left: 3em;"|₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪₪
|-
| style="padding-left: 23em;"| {{User:Tkgd2007/Userboxes/My time|+0}} {{Archive box collapsible|search=yes |[[/Archive 1]]</br>[[/Archive 2013]]</br>[[/Archive 2014]]</br>[[/Archive 2016]]</br>}}
|}


=== Drug Pipeline ===
__TOC__
Jerini's Lead Compound – Icatibant for Hereditary Angioedema (HAE)
Icatibant offers a novel subcutaneous treatment for HAE, a disease causing acute
swelling attacks in patients due to elevated levels of the hormone bradykinin. By
binding to the bradykinin receptor, Icatibant reduces the effects associated with
increased levels of bradykinin. Icatibant was in-licensed from Aventis in 2001 and is
currently in Phase III registration trials in the US, Europe, and other countries. Both
the US Food and Drug Administration (FDA) and the European Medicines Agency
(EMEA) have granted orphan drug status to Icatibant for the treatment of HAE,
potentially securing, upon approval, market exclusivity for seven and ten years,
respectively. In addition, the FDA has granted fast-track designation to Icatibant in
the indication HAE, thereby facilitating closer communication with the agency.




==== Hereditary Angioedema (HAE) ====
==[[Janet McNeill]]==
HAE, the hereditary form of angioedema, is a debilitating and potentially lifethreatening genetic disease characterized by spontaneous and recurring attacks
Hi, I saw your new article and thought it would be nice to nominate it for [[Wikipedia:Did you know]] so it will appear on the main page. I went ahead and added some scholarly sources to establish notability, and will probably weed out those publishers' pages which are not [[WP:RS|reliable sources]]. I'd also like to add a section on her writing style. You can watch the discussion at [[Template:Did you know nominations/Janet McNeill]]. Best, [[User:Yoninah|Yoninah]] ([[User talk:Yoninah|talk]]) 00:56, 2 March 2016 (UTC)
of edema (swelling) in various body parts including the hands, feet, face, throat,
:Greetings {{u|Yoninah}}. I'm delighted to see someone adding to the page. I did what I could creating it with the sources I had access to but I knew from the beginning it was limited in scope. I will watch the discussion with interest as I've never had any involvement with the DYK process.[[User:Antiqueight|<b><font color="green"> &#127866; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chat</small></sup>]] 01:08, 2 March 2016 (UTC)
and abdomen. HAE attacks in the hands, face, and feet can be disfiguring whereas
::Thanks for the barnstar! [[User:Yoninah|Yoninah]] ([[User talk:Yoninah|talk]]) 11:07, 2 March 2016 (UTC)
abdominal attacks, caused by swelling in the intestinal wall, result in severe bouts
:::{{u|Yoninah}}. I'm just buttering you up so you'll be disposed to help me when I need ;-) [[User:Antiqueight|<b><font color="green"> &#127866; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chat</small></sup>]] 12:27, 2 March 2016 (UTC)
of pain. Attacks that affect the throat can be life-threatening, as swelling constricts
::::{{smiley}} My pleasure. [[User:Yoninah|Yoninah]] ([[User talk:Yoninah|talk]]) 14:46, 2 March 2016 (UTC)
the airway and can lead to suffocation. An estimated 1:10,000-1:50,000 people in the US and Europe are affected by HAE, and HAE patients suffer an average of 12 attacks per year, each lasting about two to five days if left untreated. No adequate treatment is currently available for HAE in the US, and an intravenously administered blood product is marketed in some European countries. Jerini is also developing Icatibant for the treatment of drug-induced angioedema and expects to begin a IIa clinical trial in the fourth quarter of 2006. In addition, a proof of concept clinical trial for angio-edema in chronic idiopathic urticaria resistant to conventional therapy is planned for 2007.


== [[Louise Gavan Duffy]] ==


==== Icatibant in Other Indications ====
{{u|SusunW}}, {{u|Rosiestep}}, {{u|Jane023}}, {{u|Ipigott}}, {{u|Yoninah}}, {{u|Librarygurl}} (As the people I have had ''some'' conversation with recently and as people on and interested in Women's history) I was wondering if - if <u>one</u> of you has the time or interest - you would review/assess the article on [[Louise Gavan Duffy]] as I think it has some hope of becoming a good article but I only just wrote it...so I'm sure it needs '''work'''...but since I'm now blind to it, having spent too long working on it, I could use a hand....[[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 03:11, 4 March 2016 (UTC)
Jerini plans to broaden the therapeutic potential of Icatibant by addressing additional
:Using ORES I got http://ores.wmflabs.org/scores/enwiki/wp10/708182178/ "prediction": "GA" -Which is why I think this might be worth putting more time and effort into => but I need help/guidance.[[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 03:27, 4 March 2016 (UTC)
disease indications in which the pathophysiological role of elevated bradykinin
::impressive! I have never had the patience to figure out the whole quality thing, but I would say yes, at first glance. I noticed you have a person data template in there but that has been deprecated and these can be deleted because all info in there belongs on Wikidata. This suffragette was already in Wikidata thanks to a project from the Oxford dictionary of biography, so I linked it to this article. You can better spend any efforts on person data templates in wikidata and just delete the template if you see one. If I created the template or article, then the person data was probably coming from Wikidata to begin with anyway. Thanks for your work! [[User:Jane023|Jane]] ([[User talk:Jane023|talk]]) 06:59, 4 March 2016 (UTC)
levels has been established. Jerini has completed a Phase IIa proof of concept
::::Congrats! It is a really good start. If you want to go for GA it needs expansion and clarification on background information. The lede needs to summarize the information in the entirety of the article. Assume your reader knows nothing of Irish history. Brief descriptions are needed to familiarize the reader with the events. What is GPO? It isn't defined anywhere in the article. Upon it's first use, you should say what it is [[General Post Office, Dublin|General Post Office]] (GPO) and explain why it is sigificant. She was "born in France, the daughter of nationalist ..." French nationalist? or more likely [[Irish nationalism|Irish nationalist]]. What is "Treaty in 1921"? [[Anglo-Irish Treaty]] perhaps? You have just been talking about suffrage, when you say she joined Cumann na mBan. Probably a brief explanation of the organization's purpose will bridge the transition to it. What is the "Rising"? Under protection of the Red Cross. Which one? The [[Irish Red Cross]] was not established until 1939, so was it the [[International Red Cross]]? You say "There she found a hold out of Volunteers who were unaware the fighting was over." So are we. No where in the article did you tell the reader there was any fighting nor an end to it. "Duffy was a supporter of the Treaty"...because? What did the treaty say? What is Cumann na Saoirse? I would also suggest you review [https://tools.wmflabs.org/copyvios/?lang=en&project=wikipedia&title=Louise+Gavan+Duffy&oldid=&action=search&use_engine=1&use_links=1&turnitin=0 Earwig] and eliminate as many text duplications as possible. Hope this helps. Ping me if you have questions or want to discuss further. [[User:SusunW|SusunW]] ([[User talk:SusunW|talk]]) 07:37, 4 March 2016 (UTC)
clinical trial with Icatibant for the treatment of refractory ascites in liver cirrhosis
(RAIL). Based on data from this study and the pathophysiology of bradykinin in
RAIL, Jerini and its US partner Kos Pharmaceuticals are evaluating a more specific
subpopulation of patients with ascites. In addition, data from a Phase IIa asthma
study forms the basis for Kos and Jerini to further assess Icatibant's potential to
treat a subgroup of asthma patients. Another Icatibant program targets edema
reduction in patients hospitalized with severe burn injuries. This program is
currently in late preclinical development and has received orphan designation
from the US regulatory authority.


*The article is certainly coming along well but in addition to Susun's points, I would suggest you draw more heavily on sources from published literature. You can find a number of useful references by searching for Louise Gavan Duffy under Google books. I also think you should use the Harvard/sfn system of referencing, which requires you to produce a separate list of sources. You can find information about this at [[Wikipedia:Citing_sources#Short_citations]]. It has the advantage of allowing you to cite the page numbers of the specific references rather than grouping them under one source. Have a look at one of our recent GA articles such as [[Fatima Massaquoi]] to see how this is done. That article may also give you some ideas about how you could expand on Duffy. I would be happy to assist you with copy editing after you have followed up on our suggestions. At the moment, we are all very busy with Art+Feminism for Women's History Month but we will no doubt be able to help you along further in due course. Thanks for you efforts and good luck with the GA.--[[User:Ipigott|Ipigott]] ([[User talk:Ipigott|talk]]) 08:05, 4 March 2016 (UTC)


=== Jerini's Proprietary Peptides-to-Drugs (P2D) Platform ===
::{{u|SusunW}}, {{u|Jane023}}, {{u|Ipigott}}, Oh brilliant- thank you. Yes, I can focus on this and look up the referencing information as I know nothing about that. I indeed forgot that the whole world doesn't know about The Rising - it's the centenary year (and Easter is approaching) so it's the main topic of conversation other than the election that just happened! I will work on that too. I intend to work on the art and feminism side of things too but I have about 3 names left in my list I wanted to get through and I wasn't expecting this one to be so interesting/involving..(mind, [[Juanita Casey]] is art I think though I wrote the article thinking she was a writer). Thanks all.[[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 11:31, 4 March 2016 (UTC)
Based on its P2D platform, Jerini has established several in-house development programs, which address indications within the ophthalmology, oncology, and inflammatory therapeutic areas. The most advanced of these programs targets age-related macular degeneration (AMD), the leading cause of vision loss and blindness in people over the age of 55 in developed countries. Jerini's compound (JSM 6427) has shown significant efficacy in combating disease progression in preclinical models and is currently scheduled to enter clinical trials in Q1 2007.
:::Well frankly I was on my way to the states with Aer Lingus in January and got stuck in Dublin because of the wind, so I went downtown and saw the museum and enjoyed a guiness near Trinity College. I had an interesting conversation in the bus about the Rising and was told all about the anniversary by a very animated woman in her late 70s who got all excited when I told her about Wikipedia and she claimed there wasn't much there. So if you want to write about that, I think you should! It is Women's history month after all, and I don't know how many Wikipedians there are who could pick this up. [[User:Jane023|Jane]] ([[User talk:Jane023|talk]]) 11:41, 4 March 2016 (UTC)
Icatibant in Angioedema


:::I already included Juanita Casey on our Art+Feminist outcomes list.--[[User:Ipigott|Ipigott]] ([[User talk:Ipigott|talk]]) 11:43, 4 March 2016 (UTC)


=== Jerini’s Drug Development Technology ===
::::{{u|Jane023}} I shall look into other names for this so too...the Rising had strong art ties. {{u|Ipigott}} Oh cool! Thanks.[[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 11:49, 4 March 2016 (UTC)
Jerini's proprietary Peptides-to-Drugs (P2D) technology is used to identify peptide
drug lead structures and systematically transform them into peptidomimetic
(injectable) and small-molecule (oral) drugs, depending on the indication. As a
result, Jerini is able to develop novel drug candidates against disease targets that
are difficult to address using traditional discovery methods. The ability to create
both peptidomimetic and small-molecule drug candidates facilitates parallel
development of acute and chronic treatment possibilities for the same disease
target, providing multiple business and partnering opportunities.


:::::Nice article. Commonly, I wouldn't see an "Other reading" section in a GA article, so you might consider incorporating that material in the article and reference it accordingly. --[[User:Rosiestep|Rosiestep]] ([[User talk:Rosiestep|talk]]) 15:23, 4 March 2016 (UTC)
::::::Thank you {{u|Rosiestep}}. The other reading is from the end of one of the sources I used and it was 4am so I had no intention of trying to find the sources then...However I also hadn't thought of it as not being typical for a GA so I will do that, go through and see what I can find to cite or not..[[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 15:56, 4 March 2016 (UTC)


=== Business Collaborations ===
Although its primary focus is to discover and develop its own drug products, Jerini
collaborates with other pharmaceutical companies. These partnerships further
validate Jerini's P2D technology, and also enable the company to take advantage
of the potential commercial benefits from products generated through these
collaborations. In November 2005, Jerini and Kos Pharmaceuticals, Inc. signed an
exclusive agreement for the development, marketing, and distribution of Jerini's
compound, Icatibant, in the United States and Canada. In addition, Jerini has discovery and development collaborations with Baxter AG and Alcon Research Ltd.


RIGHT! I have made some changes- let me know your thoughts..and I'll work on actual page number references tomorrow. I think I'll create a new article for someone else tonight. I'm tired of reading the same words ;-)[[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 19:00, 4 March 2016 (UTC)


==== Collaboration Agreements ====
:Oh dear - the ORES tool? Yesterday the GA score was .4444 and today it is 0.3370. Does this mean I'm making the article worse?[[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 19:03, 4 March 2016 (UTC)
* Alcon Research Ltd.
::IMO, you are much closer to GA now. I have never used the ORES tool, so don't really know what that's all about. The tips Dr. Blofeld taught me: Make sure the articles sufficiently gives detail that someone not familiar with the subject still understands the context. Text should be 7500 characters or more. You need at least one photo with proper licensing (it can be fair use). No copyvios, adequate sourcing, harv-ref sourcing is preferred. I usually have someone I trust review and liberally edit the article before I nominate it. For me it will take up to a week or longer to prepare it for GA just to make sure I have all my ducks in a row. [[User:SusunW|SusunW]] ([[User talk:SusunW|talk]]) 22:01, 4 March 2016 (UTC)
* Baxter AG
:::Cool, thanks - it's good to know it is actually getting better. I'm not that concerned by the ORES tool except that it gave me the push to improve this article in the first place :-). I have no clue how I'm going to get a photo. It may have to be something fairly generic unless I can get someone closer to the national library to see if they have something copywrite free. I will leave it for a day or so and come back with fresh eyes (if I can stop playing with it). Thank you so much for your input. I have only recently started seriously creating articles and have no idea about what makes it better.[[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 22:13, 4 March 2016 (UTC)
* KOS Pharmaceuticals, Inc.
:::::If the National Library does not have public domain images, you can clip and upload 1 non-free image as fair use with the justification that she is dead. Here's one I did which shows you how to justify it [https://en.wikipedia.org/wiki/File:Joceline_Clemencia.jpg] [[User:SusunW|SusunW]] ([[User talk:SusunW|talk]]) 23:18, 4 March 2016 (UTC)
* sanofi-aventis
::::::Oh! I didn't know you could do that at all![[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 23:35, 4 March 2016 (UTC)


==Disambiguation link notification for March 4==


=== Upcoming Milestones ===
Hi. Thank you for your recent edits. Wikipedia appreciates your help. We noticed though that you've added some links pointing to [[Wikipedia:Disambiguation|disambiguation pages]]. Such links are almost always unintended, since a disambiguation page is merely a list of "Did you mean..." article titles. <small>Read the [[User:DPL bot/Dablink notification FAQ|FAQ]]{{*}} Join us at the [[Wikipedia:Disambiguation pages with links|DPL WikiProject]].</small>
* Report top line HAE Phase III data: Q3 2006
* Submit marketing authorization applications: Q4 2006
* Start of Phase I AMD clinical trial: Q1 2007
* Start of Phase IIa drug-induced angioedema trial: Q4 2006/Q1 2007


:[[Juanita Casey]] ([http://dispenser.homenet.org/~dispenser/cgi-bin/dablinks.py/Juanita_Casey check to confirm]&nbsp;|&nbsp;[http://dispenser.homenet.org/~dispenser/cgi-bin/dab_solver.py/Juanita_Casey fix with Dab solver])
::added a link pointing to [[St Ives]]


=== Facts ===
:[[Louise Gavan Duffy]] ([http://dispenser.homenet.org/~dispenser/cgi-bin/dablinks.py/Louise_Gavan_Duffy check to confirm]&nbsp;|&nbsp;[http://dispenser.homenet.org/~dispenser/cgi-bin/dab_solver.py/Louise_Gavan_Duffy fix with Dab solver])
* Start of operations in 1994
::added a link pointing to [[Michael Collins]]
* 125 Employees
* Lead product in Phase III clinical trials
* Proprietary Peptides-to-Drugs (P2D) technology platform
* Subsidiaries: JPT Peptide Technologies GmbH, Jerini US, Inc.


:[[Nine Graces]] ([http://dispenser.homenet.org/~dispenser/cgi-bin/dablinks.py/Nine_Graces check to confirm]&nbsp;|&nbsp;[http://dispenser.homenet.org/~dispenser/cgi-bin/dab_solver.py/Nine_Graces fix with Dab solver])
::added a link pointing to [[Britain]]


=== Financing History ===
It's OK to remove this message. Also, to stop receiving these messages, follow these [[User:DPL bot|opt-out instructions]]. Thanks, [[User:DPL bot|DPL bot]] ([[User talk:DPL bot|talk]]) 11:28, 4 March 2016 (UTC)
Jerini is listed on the Prime Standard of the Frankfurt Stock Exchange (JI4), and has raised a total of over 130 Mio. Euro in public and private financing to date.


== Women's role in the Easter Risinig ==


=== Management ===
Women artists are clearly eligible for Art&Feminism, but I was talking to the woman in the bus about women like [[Margaret Skinnider]].Now it looks like she was the only one. Best, [[User:Jane023|Jane]] ([[User talk:Jane023|talk]]) 14:30, 4 March 2016 (UTC)
*Jens Schneider-Mergener, Chief Executive Officer
:Not sure what you mean by only one. She may have been the only one thus injured but she wasn't the only woman fighting in the rising. Though mostly the women were in more support roles like messenger, cook and nurse, not all of them were. However the more exciting thing is that I just discovered one of the women (though not in the Rising itself) involved in the whole nationalist thing was in fact the old women my mother knew. I had no clue she was involved at all! I will find more stories!![[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 14:57, 4 March 2016 (UTC)
*Adi Hoess, Chief Commercial Officer
::''I will find more stories!!'' By which I mean more women with stories. More women in the Easter rising or going forward, the War of Independence or Civil War.[[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 16:04, 4 March 2016 (UTC)
*Jochen Knolle, Chief Scientific Officer, Head of R & D
That is pretty cool. I think because of the centennial that now is the time to capture those stories, because the enthusiasm is there. If you write it, I'm sure readers will appreciate having it available as the remembrance stories start to get published around the various gatherings and events. Good luck tracking down sources for all that stuff though! [[User:Jane023|Jane]] ([[User talk:Jane023|talk]]) 23:39, 4 March 2016 (UTC)
*Berndt Modig, Chief Financial Officer


==[[Louise Gavan Duffy]] citations==
Whatever you did to this article the citation style now throws up lots of red errors. It was much better back like [https://en.wikipedia.org/w/index.php?title=Louise_Gavan_Duffy&type=revision&diff=708277451&oldid=708276321 this edit]. Can you fix it? [[User:Ww2censor|ww2censor]] ([[User talk:Ww2censor|talk]]) 10:47, 5 March 2016 (UTC)
: I don't understand. I don't see any red errors? [[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 12:42, 5 March 2016 (UTC)
:: Hi (I'm one of [[user:Ipigott]]'s page stalkers). The red errors show up if you install [[User:Ucucha/HarvErrors]], which I highly recommend if you are using {{tlx|sfn}} and friends. Sfn uses a link identifier generated from its parameters. {{tlx|cite book}} and friends can generate the same link identifier from their last* and date or year parameters, which is the normal way of using sfn. If you use hand-crafted text for the intermediate links (as you are at present) you need to provide the |ref= parameters with exactly the same definition which sfn generates. The cleanest way to do that is to use {{tlx|harvid}} as I have done in [//en.wikipedia.org/w/index.php?title=Louise_Gavan_Duffy&type=revision&diff=708417401&oldid=708389767 this edit].
:: My suggestion is to take advantage of the default behaviour of sfn when the corresponding citation has author surnames and date, and in other cases to use the |work= parameter from the citation (see the handing of ''Dragonholder'' references in [[Anne McCaffrey]] for an example). That would require more extensive changes to the article that the above example edit, but the result would be nice and tidy. If you like I can update a few of the citations as a further example for you... --[[User:Mirokado|Mirokado]] ([[User talk:Mirokado|talk]]) 14:09, 5 March 2016 (UTC)
:::I wondered how you appeared to help in so timely a manner! Yes, as you say - I'm editing by hand on these citations- I was using Prove IT but it doesn't cite that way and besides it usually annoys me. I am glad of your help. If the page is at least not broken now, then I will take time to read and review the above - I won't have a chance most likely before Monday- although I say that and will probably do it at 2am when insomnia hits. If you could add the few examples it would be great as I can initially copy from that. If the page is still showing faults let me know so I can at least fix those.[[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 14:16, 5 March 2016 (UTC)


=== Contact ===
OH! I have that script loaded now and there are errors everywhere![[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 14:20, 5 March 2016 (UTC)
Stacy Wiedenmann, Director Investor Relations & Corporate Communications <br/>
Fixed[[User:Antiqueight|<b><font color="Cadmium red"> &#9749; Antiqueight</font></b>]] [[User talk:Antiqueight|<sup><small>chatter</small></sup>]] 14:28, 5 March 2016 (UTC)
Jerini AG, Invalidenstrasse 130, 10115 Berlin, Germany <br/>
: Yes it is very helpful! I will provide a few examples of what I am suggesting above, a bit later. --[[User:Mirokado|Mirokado]] ([[User talk:Mirokado|talk]]) 14:35, 5 March 2016 (UTC)
[mailto:wiedenmann@jerini.com wiedenmann@jerini.com] [http://www.jerini.com www.jerini.com]

::Thanks {{u|Mirokado}} for helping out with this. You are far more experienced in this kind of referencing than I am.--[[User:Ipigott|Ipigott]] ([[User talk:Ipigott|talk]]) 15:04, 5 March 2016 (UTC)

==DYK answers==
Hi, Antiqueight, thanks for asking. When you write an article and post it, how many people will read it? The way to get articles viewed is to link them to lots of other pages. Then, when someone reads that other page, they'll click on your article, too. But when you nominate your new article for DYK, then it (in the form of a hook) appears on the main page, where it will be viewed by thousands of readers in a 12-hour period! Even my most boring hooks get at least 1,000 hits, and a really good hook can get many more thousands. So yes, if you want your new article to get the most exposure, nominate it for DYK within 7 days of creation.

DYK is known for having a lot of rules. They say the main reason why articles have to be less than 7 days old is because DYK wants to feature ''new'' content. However, there are several avenues to nomination. The article could be:
#newly created within the last 7 days
#5 times expanded within the last 7 days (so if you wrote a short article a while back, you could expand the character count 5x to qualify for DYK)
#[[WP:GA|GA]]-approved within the last 7 days (so if you wrote any article a while back, you could add referencing/images to get it up to GA standards, get the GA approval, and then nominate it for DYK)

The hook has to have an [[WP:INLINE|inline cite]] to a reliable source. A [[WP:PRIMARY|primary reference]] like the subject's own website is fine. I'm not exactly clear where you found her quote; is it something she told you personally? [[User:Yoninah|Yoninah]] ([[User talk:Yoninah|talk]]) 22:33, 8 March 2016 (UTC)
::Cool - thank you so much for the reply - her quote is in her military witness statement which is one of the references I do use in the article but I didn't specifically reference the quote. I can go add it? Then that article and the one I've just written seem like something that would be good to work with - the one I've just written I have to look for better back up sources but at one point people complained about her being an examiner (because she was a woman) - she was examining midwifery!! What do you think?[[User:Antiqueight|<em style="font-family: Mistral; color:red"> &#9749; Antiqueight</em>]] [[User talk:Antiqueight|<sup><small>haver</small></sup>]] 22:40, 8 March 2016 (UTC)
:::If you add an inline cite (right after the sentence in question), then a military witness statement sounds fine. If you want me to look at specific articles, please give me links to them. [[User:Yoninah|Yoninah]] ([[User talk:Yoninah|talk]]) 22:53, 8 March 2016 (UTC)
::::Ha! oops - yes, that would help! [[Emily Winifred Dickson]] <-Not actually finished yet but likely to be tomorrow because I'm running out of energy....and [[Elizabeth Bloxham]] <-which I'll add the quote to in a few minutes..[[User:Antiqueight|<em style="font-family: Mistral; color:red"> &#9749; Antiqueight</em>]] [[User talk:Antiqueight|<sup><small>haver</small></sup>]] 22:59, 8 March 2016 (UTC)
:::::OK, I'll look at them tomorrow after you've finished. You could also tell me the hooks you want to use, and I'll let you know if they work. [[User:Yoninah|Yoninah]] ([[User talk:Yoninah|talk]]) 23:07, 8 March 2016 (UTC)
::::::Thanks {{u|Yoninah}} -Apparently I'm far too tired now - I pulled one quote out but it sucks I think. I'll do it tomorrow and let you know. Thanks - I never really thought about DYK because I never use the main page for wikipedia myself![[User:Antiqueight|<em style="font-family: Mistral; color:red"> &#9749; Antiqueight</em>]] [[User talk:Antiqueight|<sup><small>haver</small></sup>]] 23:14, 8 March 2016 (UTC)

==DYK for Janet McNeill==
{{tmbox
|type = notice
|image = [[Image:Updated DYK query.svg|15px|Updated DYK query]]
|text = On [[Wikipedia:Recent_additions#10 March 2016|10 March 2016]], '''[[:Template:Did you know|Did you know]]''' was updated with a fact from the article '''''[[Janet McNeill]]''''', which you recently created, substantially expanded, or brought to good article status. The fact was ''... that '''[[Janet McNeill]]''', a prolific [[Irish people|Irish]] writer of adult and children's fiction, peopled her adult novels with "menopausal, middle-aged, middle-class Protestants"?'' {{#if: |The nomination discussion and review may be seen at [[]].|{{#ifexist:Template:Did you know nominations/Janet McNeill|The nomination discussion and review may be seen at [[Template:Did you know nominations/Janet McNeill]].|{{#ifexist:Template talk:Did you know/Janet McNeill|The nomination discussion and review may be seen at [[Template talk:Did you know/Janet McNeill]].}} }} }} You are welcome to check how many page hits the article got while on the front page <small>([[User:Rjanag/Pageview stats|here's how]], [//tools.wmflabs.org/pageviews#start=2016-02-29&end=2016-03-20&project=en.wikipedia.org&pages=Janet_McNeill daily totals])</small>, and it may be added to [[Wikipedia:Did you know/Statistics|the statistics page]] if the total is over 5,000. Finally, if you know of an interesting fact from another recently created article, then please feel free to suggest it on the [[:Template talk:Did you know|Did you know talk page]].
}}<!-- Template:UpdatedDYK --> '''<span style="color:#880000;">—♦♦ </span>[[User:Amberrock|<span style="color:#880000;">''AMBER''</span>]][[User talk:Amberrock|<span style="color:#FF6600;"><sup>(ЯʘCK)</sup></span>]]''' 00:01, 10 March 2016 (UTC)

Revision as of 09:07, 21 August 2006

Jerini AG

Jerini is a pharmaceutical company based in Berlin, Germany, focusing on the

discovery and development of novel peptide-based drugs. Using its proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursues disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini has established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy is to market new drugs in niche indications independently and in larger indications with partners.


Drug Pipeline

Jerini's Lead Compound – Icatibant for Hereditary Angioedema (HAE) Icatibant offers a novel subcutaneous treatment for HAE, a disease causing acute swelling attacks in patients due to elevated levels of the hormone bradykinin. By binding to the bradykinin receptor, Icatibant reduces the effects associated with increased levels of bradykinin. Icatibant was in-licensed from Aventis in 2001 and is currently in Phase III registration trials in the US, Europe, and other countries. Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) have granted orphan drug status to Icatibant for the treatment of HAE, potentially securing, upon approval, market exclusivity for seven and ten years, respectively. In addition, the FDA has granted fast-track designation to Icatibant in the indication HAE, thereby facilitating closer communication with the agency.


Hereditary Angioedema (HAE)

HAE, the hereditary form of angioedema, is a debilitating and potentially lifethreatening genetic disease characterized by spontaneous and recurring attacks of edema (swelling) in various body parts including the hands, feet, face, throat, and abdomen. HAE attacks in the hands, face, and feet can be disfiguring whereas abdominal attacks, caused by swelling in the intestinal wall, result in severe bouts of pain. Attacks that affect the throat can be life-threatening, as swelling constricts the airway and can lead to suffocation. An estimated 1:10,000-1:50,000 people in the US and Europe are affected by HAE, and HAE patients suffer an average of 12 attacks per year, each lasting about two to five days if left untreated. No adequate treatment is currently available for HAE in the US, and an intravenously administered blood product is marketed in some European countries. Jerini is also developing Icatibant for the treatment of drug-induced angioedema and expects to begin a IIa clinical trial in the fourth quarter of 2006. In addition, a proof of concept clinical trial for angio-edema in chronic idiopathic urticaria resistant to conventional therapy is planned for 2007.


Icatibant in Other Indications

Jerini plans to broaden the therapeutic potential of Icatibant by addressing additional disease indications in which the pathophysiological role of elevated bradykinin levels has been established. Jerini has completed a Phase IIa proof of concept clinical trial with Icatibant for the treatment of refractory ascites in liver cirrhosis (RAIL). Based on data from this study and the pathophysiology of bradykinin in RAIL, Jerini and its US partner Kos Pharmaceuticals are evaluating a more specific subpopulation of patients with ascites. In addition, data from a Phase IIa asthma study forms the basis for Kos and Jerini to further assess Icatibant's potential to treat a subgroup of asthma patients. Another Icatibant program targets edema reduction in patients hospitalized with severe burn injuries. This program is currently in late preclinical development and has received orphan designation from the US regulatory authority.


Jerini's Proprietary Peptides-to-Drugs (P2D) Platform

Based on its P2D platform, Jerini has established several in-house development programs, which address indications within the ophthalmology, oncology, and inflammatory therapeutic areas. The most advanced of these programs targets age-related macular degeneration (AMD), the leading cause of vision loss and blindness in people over the age of 55 in developed countries. Jerini's compound (JSM 6427) has shown significant efficacy in combating disease progression in preclinical models and is currently scheduled to enter clinical trials in Q1 2007. Icatibant in Angioedema


Jerini’s Drug Development Technology

Jerini's proprietary Peptides-to-Drugs (P2D) technology is used to identify peptide drug lead structures and systematically transform them into peptidomimetic (injectable) and small-molecule (oral) drugs, depending on the indication. As a result, Jerini is able to develop novel drug candidates against disease targets that are difficult to address using traditional discovery methods. The ability to create both peptidomimetic and small-molecule drug candidates facilitates parallel development of acute and chronic treatment possibilities for the same disease target, providing multiple business and partnering opportunities.


Business Collaborations

Although its primary focus is to discover and develop its own drug products, Jerini collaborates with other pharmaceutical companies. These partnerships further validate Jerini's P2D technology, and also enable the company to take advantage of the potential commercial benefits from products generated through these collaborations. In November 2005, Jerini and Kos Pharmaceuticals, Inc. signed an exclusive agreement for the development, marketing, and distribution of Jerini's compound, Icatibant, in the United States and Canada. In addition, Jerini has discovery and development collaborations with Baxter AG and Alcon Research Ltd.


Collaboration Agreements

  • Alcon Research Ltd.
  • Baxter AG
  • KOS Pharmaceuticals, Inc.
  • sanofi-aventis


Upcoming Milestones

  • Report top line HAE Phase III data: Q3 2006
  • Submit marketing authorization applications: Q4 2006
  • Start of Phase I AMD clinical trial: Q1 2007
  • Start of Phase IIa drug-induced angioedema trial: Q4 2006/Q1 2007


Facts

  • Start of operations in 1994
  • 125 Employees
  • Lead product in Phase III clinical trials
  • Proprietary Peptides-to-Drugs (P2D) technology platform
  • Subsidiaries: JPT Peptide Technologies GmbH, Jerini US, Inc.


Financing History

Jerini is listed on the Prime Standard of the Frankfurt Stock Exchange (JI4), and has raised a total of over 130 Mio. Euro in public and private financing to date.


Management

  • Jens Schneider-Mergener, Chief Executive Officer
  • Adi Hoess, Chief Commercial Officer
  • Jochen Knolle, Chief Scientific Officer, Head of R & D
  • Berndt Modig, Chief Financial Officer


Contact

Stacy Wiedenmann, Director Investor Relations & Corporate Communications
Jerini AG, Invalidenstrasse 130, 10115 Berlin, Germany
wiedenmann@jerini.com www.jerini.com

Retrieved from "https://en.wikipedia.org/w/index.php?title=User_talk:Antiqueight&oldid=70926136"